Tradestie Institutional Equity Comparison Engine

SRZN vs PYPD โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

PYPD Overall Edge

PYPD Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to PolyPid Ltd. Ordinary Shares (PYPD) driven by superior Momentum & Technical, Options & Structure while SRZN counters with relative strength in Growth & Margin. Fundamentally, SRZN trades at N/M Forward P/E with -485.4% operating margin (+408.6% YoY revenue) versus PYPD at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, SRZN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro) against PYPD sits in BREAKOUT (12th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
SRZN N/M vs PYPD N/M Fwd P/E
Growth & Margin Winner SRZN
Op Margin -485.4% vs 0.0% ยท YoY +408.6% vs +0.0%
Momentum & Technical Winner PYPD
1Y +130.6% vs +81.0% ยท 52W Pos 69% vs 82%
Options & Structure Winner PYPD
CONSOLIDATION (5th %ile IV) vs BREAKOUT (12th %ile IV)
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$29.93
-7.38% 1D
Market Cap $602.5M
1M Return +25.57%
1Y Return +130.62%
Forward P/E N/M
Unified AI Score
33.2 / 100 SELL
Tech 50.0 Fund 34.0 Flow 65.0 Mom 40.0
PYPD NASDAQ
PolyPid Ltd. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.50
+5.63% 1D
Market Cap $132.2M
1M Return +33.12%
1Y Return +80.95%
Forward P/E N/M
Unified AI Score
31.1 / 100 SELL
Tech 50.0 Fund 27.0 Flow 56.0 Mom 32.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SRZN +130.62% PYPD +80.95% Spread: +49.67 pp (SRZN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SRZN TTM Op. Margin: -485.4% PYPD TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SRZN vs PYPD. Trailing 12-month operating profitability (SRZN -485.4% vs PYPD 0.0%) and valuation multiples (SRZN N/M vs PYPD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SRZN (4) vs PYPD (3)
Institutional Metric SRZN PYPD Criterion Row Winner
Market Capitalization Scale $602.5M $132.2M Larger Scale SRZN
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +408.6% +0.0% Higher Growth SRZN
Operating Margin (TTM) Profitability -485.4% 0.0% Higher Margin PYPD
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -62.8% -243.6% Higher ROE SRZN
52-Week Range Position Momentum 69% ($12โ€“$38) 82% ($4โ€“$7) Stronger Trend PYPD
Beta / 30D Volatility Risk Regime 1.28ฮฒ ยท 66% Vol 0.88ฮฒ ยท 59% Vol Lower Realized Risk PYPD
Unified Institutional Score Composite Signal 33.2 / 100 (SELL) 31.1 / 100 (SELL) Higher Composite SRZN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SRZN vs PYPD Buy Guide
SRZN CONSOLIDATION
38d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live SRZN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
PYPD BREAKOUT
40d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 12th %ile
IV Regime Compressed (<25th %ile)
Live PYPD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SRZN nor PYPD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.